Glen Research, a Maravai LifeSciences company and leader in the development of a wide range of reagents for DNA and RNA synthesis, announced today that it has achieved ISO 9001:2015 certification. This designation certifies a high level of quality assurance and consistency and will be particularly important to Glen Research customers engaged in diagnostic and pharmaceutical discovery.
ISO is the International Organization for Standardization, and certification is a demonstration of Glen Research’s commitment to continuously deliver high-quality products. ISO standards help guide manufacturing and quality-control processes, documentation systems, customer service, product design and distribution and other support functions.
“The process of getting this certification takes several years,” said Christine Dolan, COO of Glen Research. “Attaining the ISO designation is really a starting point because there are certain steps that must be taken every year to maintain certification and ensure continual improvement of processes. The discipline and documentation that are required will give our customers confidence and give us a competitive edge.”
“Following the ISO framework helps us improve productivity, enhance customer satisfaction and ensure business continuity,” said Ericka Crawford, vice president of quality for Maravai LifeSciences. “It’s a win for us and a win for our customers.”
For more than 30 years, Glen Research has been providing key products for oligonucleotide synthesis including phosphoramidites and supports, modifiers and oligonucleotide purification. The company serves customers worldwide in basic research, diagnostics and therapeutics. Glen Research is headquartered in Sterling, Virginia and was acquired by Maravai LifeSciences in 2017.
David Weber, Chief Commercial Officer